Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
NCT01275664 · Gynecologic Oncology Group · NA · terminated · last registry update 2018-05-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to no patient population available” | – | Registry record, Gynecologic Oncology Group |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-05-22Also stopped (withdrawn): Costantine Albany, Rolapitant + Palonosetron (NCT03960151)
- 2019-05-09Results posted on the registry: Joseph Ma, Netupitant and Palonosetron (NCT03008213)
- 2019-05-08Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Aprepitant + Placebo (NCT01149369)
- 2019-03-15Also stopped (terminated): Merck Sharp & Dohme LLC, Fosaprepitant + Placebo for fosaprepitant (NCT02519842)
- 2019-03-15Phase 3 first posted: Mahidol University, aprepitant + olanzapine 10 mg (NCT03876938)
- 2019-03-12Results posted on the registry: Acacia Pharma Ltd, Ondansetron + Placebo (NCT01857232)
- 2019-03-07Results posted on the registry: Vanderbilt University, Propofol + Sevoflurane (NCT02625181)
- 2019-03-05Results posted on the registry: Vyne Therapeutics Inc., Serlopitant High Dose + Placebo Oral Tablet (NCT02975206)
- 2019-01-18Phase 3 first posted: University Hospital, Brest, Aprepitant 80 mg + Hydroxyzine 25mg (NCT03808805)
- 2018-10-30Results posted on the registry: Dartmouth-Hitchcock Medical Center, Aprepitant + Placebo (NCT01854177)
- 2018-09-25Also stopped (terminated): Merck Sharp & Dohme LLC, Experimental: aprepitant + Experimental: fosaprepitant (NCT00818259)
- 2018-09-19Phase 3 first posted: Vyne Therapeutics Inc., 5mg Serlopitant Tablets + Placebo Tablets (NCT03677401)
- 2018-09-17Phase 3 first posted: Sun Yat-sen University, Aprepitant + Palonosetron (NCT03674294)
- 2018-09-12Phase 3 first posted: Christina Ruhlmann, Akynzeo + Dexamethasone (NCT03668639)
- 2018-08-27Also stopped (terminated): Merck Sharp & Dohme LLC, Fosaprepitant dimeglumine + 5-HT3 RA (NCT01405924)
- 2018-08-20Results posted on the registry: Augusta University, Olanzapine + Placebo (NCT02635984)
- 2018-07-30Phase 3 first posted: Instituto Nacional de Cancerologia de Mexico, Palonosetron + Ondansetron (NCT03606369)
- 2018-07-27Results posted on the registry: Loyola University, Standard PO (Zofran + Dexamethason) + Aprepitant (MK-869) + Standard PO (NCT00781768)
- 2018-07-05Phase 3 first posted: Alliance for Clinical Trials in Oncology, Palonosetron Hydrochloride + Ondansetron Hydrochloride (NCT03578081)
- 2018-06-26Phase 3 first posted: Vanda Pharmaceuticals, Tradipitant + Placebo (NCT03568331)
- 2018-06-26Results posted on the registry: Katy Peters, aprepitant + ondansetron (NCT01450826)
- 2018-06-20Results posted on the registry: Helsinn Healthcare SA, Pro-netupitant/Palonosetron + Netupitant/Palonosetron (NCT02517021)
- 2018-06-07Also stopped (terminated): St. Louis University, Fosaprepitant (NCT01874119)
- 2018-06-06Phase 3 first posted: Vyne Therapeutics Inc., 5mg Serlopitant Tablets + Placebo Tablets (NCT03546816)
- 2018-05-30Phase 3 first posted: Vyne Therapeutics Inc., 5 mg Serlopitant Tablets (NCT03540160)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision